Nuvectis Pharma, Inc. (NVCT) stock
NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$19.11−1.13 (-5.58%)
Close on Nov 16, 2026Market cap $622.63MP/E –Yield 0.00%
Nuvectis Pharma r&d expenses
Research and development expenses are spending on new products and technology.
Nuvectis Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $19.65M, up 34.5% year over year. For fiscal 2025 it was $18.15M, up 40.5% from the year before. The highest annual figure on record is $18.15M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.15M | +40.5% |
| FY2024 | Dec 31, 2024 | $12.92M | -16.0% |
| FY2023 | Dec 31, 2023 | $15.38M | +16.3% |
| FY2022 | Dec 31, 2022 | $13.23M | +38.6% |
| FY2021 | Dec 31, 2021 | $9.55M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.68M | +29.6% |
| Q1 FY2026 | Mar 31, 2026 | $4.11M | +11.6% |
| Q4 FY2025 | Dec 31, 2025 | $5.09M | +13.1% |
| Q3 FY2025 | Sep 30, 2025 | $5.77M | +104.8% |
| Q2 FY2025 | Jun 30, 2025 | $3.61M | +22.8% |
| Q1 FY2025 | Mar 31, 2025 | $3.68M | +38.3% |
| Q4 FY2024 | Dec 31, 2024 | $4.50M | +5.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.82M | -37.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.94M | -30.9% |
| Q1 FY2024 | Mar 31, 2024 | $2.66M | +12.4% |
| Q4 FY2023 | Dec 31, 2023 | $4.27M | -3.0% |
| Q3 FY2023 | Sep 30, 2023 | $4.49M | -0.8% |
| Q2 FY2023 | Jun 30, 2023 | $4.26M | +70.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.37M | +31.1% |
| Q4 FY2022 | Dec 31, 2022 | $4.40M | +284.4% |
| Q3 FY2022 | Sep 30, 2022 | $4.52M | +8.8% |
| Q2 FY2022 | Jun 30, 2022 | $2.51M | -41.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.81M | – |
| Q4 FY2021 | Dec 31, 2021 | $1.14M | – |
| Q3 FY2021 | Sep 30, 2021 | $4.16M | – |
| Q2 FY2021 | Jun 30, 2021 | $4.25M | – |
See a number that looks wrong?